I-Chow Hsu1, Daniel Hunt2, William Straube3, Jean Pouliot4, Adam Cunha4, Devan Krishnamurthy4, Howard Sandler5. 1. Department of Radiation Oncology, University of California San Francisco, San Francisco, California. Electronic address: ihsu@radonc.ucsf.edu. 2. RTOG Statistical Center, Philadelphia, Pennsylvania. 3. Image-Guided Therapy Center, St Louis, Missouri. 4. Department of Radiation Oncology, University of California San Francisco, San Francisco, California. 5. Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.
Abstract
PURPOSE: Radiation Therapy Oncology Group 0321 is the first multi-institutional cooperative group high-dose-rate (HDR) prostate brachytherapy trial with complete digital brachytherapy dosimetry data. This is a descriptive report of the data and an analysis of toxicity. METHODS AND MATERIALS: Patients are treated with external beam radiation therapy at 45 Gy and 1 HDR implant with 19 Gy in 2 fractions. Implants are done with transrectal ultrasound guidance, and computed tomography (CT)-compatible nonmetallic catheters. HDR planning is done on ≤3-mm-thick CT slices. The "mean DVH" (dose-volume histogram) of the planning target volume (PTV), implanted volume (IP), and organs at risk are calculated. This includes the mean and standard deviation (SD) of the volume at 10-percentage-point intervals from 10% to 200% of the prescribed dose. The conformal index (COIN), homogeneity index (HI), catheters per implant, and patients per institution are calculated. Multivariate analysis and hazard ratios calculation of all the variables against reported grade ≥2 (G2+) genitourinary (GU) adverse events (Common Terminology Criteria for Adverse Events, version 3) are performed. RESULTS: Dosimetry data are based on 122 eligible patients from 14 institutions. The mean of PTV, IP, catheters per implant, and patients per institution are 54 cc, 63 cc, 19 and 9, respectively. The mean of %V100PTV, V80Bladder, V80Rectum, and V120Urethra were 94%, 0.40 cc, 0.15 cc, and 0.25 cc, respectively. There are too few G2+ gastrointestinal adverse event (GI AE) for correlative analysis; thus, the analysis has been performed on the more common G2+ GU AE. There are positive correlations noted between both acute and late G2+ GU AE and urethral dose at multiple levels. Positive correlations with late AE are seen with PTV and IP at high-dose levels. A negative correlation is seen between HI and acute AE. A higher patient accrual rate is associated with a lower rate of G2+ acute and late AE. CONCLUSIONS: Higher urethral dose, larger high-dose volumes, and lower dose homogeneity are associated with greater toxicities. A mean dose-volume histogram comparison at all dose levels should be used for quality control and future research comparison. Published by Elsevier Inc.
PURPOSE: Radiation Therapy Oncology Group 0321 is the first multi-institutional cooperative group high-dose-rate (HDR) prostate brachytherapy trial with complete digital brachytherapy dosimetry data. This is a descriptive report of the data and an analysis of toxicity. METHODS AND MATERIALS: Patients are treated with external beam radiation therapy at 45 Gy and 1 HDR implant with 19 Gy in 2 fractions. Implants are done with transrectal ultrasound guidance, and computed tomography (CT)-compatible nonmetallic catheters. HDR planning is done on ≤3-mm-thick CT slices. The "mean DVH" (dose-volume histogram) of the planning target volume (PTV), implanted volume (IP), and organs at risk are calculated. This includes the mean and standard deviation (SD) of the volume at 10-percentage-point intervals from 10% to 200% of the prescribed dose. The conformal index (COIN), homogeneity index (HI), catheters per implant, and patients per institution are calculated. Multivariate analysis and hazard ratios calculation of all the variables against reported grade ≥2 (G2+) genitourinary (GU) adverse events (Common Terminology Criteria for Adverse Events, version 3) are performed. RESULTS: Dosimetry data are based on 122 eligible patients from 14 institutions. The mean of PTV, IP, catheters per implant, and patients per institution are 54 cc, 63 cc, 19 and 9, respectively. The mean of %V100PTV, V80Bladder, V80Rectum, and V120Urethra were 94%, 0.40 cc, 0.15 cc, and 0.25 cc, respectively. There are too few G2+ gastrointestinal adverse event (GI AE) for correlative analysis; thus, the analysis has been performed on the more common G2+ GU AE. There are positive correlations noted between both acute and late G2+ GU AE and urethral dose at multiple levels. Positive correlations with late AE are seen with PTV and IP at high-dose levels. A negative correlation is seen between HI and acute AE. A higher patient accrual rate is associated with a lower rate of G2+ acute and late AE. CONCLUSIONS: Higher urethral dose, larger high-dose volumes, and lower dose homogeneity are associated with greater toxicities. A mean dose-volume histogram comparison at all dose levels should be used for quality control and future research comparison. Published by Elsevier Inc.
Authors: W Robert Lee; Kyounghwa Bae; Colleen A Lawton; Michael T Gillin; Gerard Morton; Selim Firat; Madhava Baikadi; Michael Kuettel; Kathryn Greven; Howard Sandler Journal: Brachytherapy Date: 2006 Oct-Dec Impact factor: 2.362
Authors: Pirus Ghadjar; Cyrill A Rentsch; Bernhard Isaak; Frank Behrensmeier; George N Thalmann; Daniel M Aebersold Journal: Brachytherapy Date: 2010-10-28 Impact factor: 2.362
Authors: D Baltas; C Kolotas; K Geramani; R F Mould; G Ioannidis; M Kekchidi; N Zamboglou Journal: Int J Radiat Oncol Biol Phys Date: 1998-01-15 Impact factor: 7.038
Authors: Cynthia Ménard; Robert C Susil; Peter Choyke; Gary S Gustafson; William Kammerer; Holly Ning; Robert W Miller; Karen L Ullman; Nancy Sears Crouse; Sharon Smith; Etienne Lessard; Jean Pouliot; Victor Wright; Elliot McVeigh; C Norman Coleman; Kevin Camphausen Journal: Int J Radiat Oncol Biol Phys Date: 2004-08-01 Impact factor: 7.038
Authors: Pirus Ghadjar; Tamara Keller; Cyrill A Rentsch; Bernhard Isaak; Frank Behrensmeier; Andrea Stroux; George N Thalmann; Daniel M Aebersold Journal: Brachytherapy Date: 2008-11-26 Impact factor: 2.362
Authors: Nainesh Parikh; Edward Keshishian; Ayushman Sharma; Monica Roca; Brandon Manley; Michael Poch; G Daniel Grass; Javier Torres-Roca; David Boulware; Peter Johnstone; Michael Montejo; Johnna Smith; Julio Pow-Sang; Kosj Yamoah Journal: Adv Radiat Oncol Date: 2020-04-14
Authors: Lara Hathout; Michael R Folkert; Marisa A Kollmeier; Yoshiya Yamada; Gil'ad N Cohen; Michael J Zelefsky Journal: Int J Radiat Oncol Biol Phys Date: 2014-10-01 Impact factor: 7.038
Authors: I-Chow Hsu; Joseph P Rodgers; Katsuto Shinohara; James Purdy; Jeff Michalski; Mack Roach; Eric Vigneault; Robert A Ivker; Rodger M Pryzant; Michael Kuettel; Daniel Taussky; Gary S Gustafson; Adam Raben; Howard M Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2020-11-10 Impact factor: 8.013
Authors: Christopher H Chapman; Steve E Braunstein; Jean Pouliot; Susan M Noworolski; Vivian Weinberg; Adam Cunha; John Kurhanewicz; Alexander R Gottschalk; Mack Iii Roach; I-Chow Hsu Journal: J Contemp Brachytherapy Date: 2018-06-29